Live Breaking News & Updates on Erdafitinib balversa
Stay updated with breaking news from Erdafitinib balversa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FGFR2 inhibitor RLY-4008 generated early evidence of efficacy in patients with cholangiocarcinoma harboring FGFR2 fusions, according to findings from the phase 1/2 ReFocus trial, which were presented at the 2023 ASCO Annual Meeting. ....
CHICAGO — Erdafitinib improved OS, PFS and objective response rate compared with chemotherapy among patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations. Results of the phase 3 THOR trial, presented at ASCO Annual Meeting 2023, showed the FGFR inhibitor reduced the risk for death by 36% among the patient population compared with ....
Erdafitinib reduced the risk of death by 36% vs investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who were previously treated with anti–PD-1 therapy, according to findings from the phase 3 THOR trial. ....
MarkNtel Advisors has released a brand-new research study with a thorough analysis of the Bladder Cancer Treatment Market. Stakeholders can profit from ....